Incyte

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Operating cost, Ruxolitinib, SG, Tafasitamab, DLBCL, G&A, Patient, Administration, Research and development, R, Asset, Indolent lymphoma, Fine chemical, Cryptocurrency, Assurance services, Bookkeeping, Music, MorphoSys, Incyte

In addition, the first quarter of 2023 included a one-time effect from severance payments related to the restructuring of the research department.

Key Points: 
  • In addition, the first quarter of 2023 included a one-time effect from severance payments related to the restructuring of the research department.
  • Full Year 2023 Financial Guidance:
    100% of Monjuvi U.S. net product sales are recorded on MorphoSys’ income statement and related profit/loss is split 50/50 between MorphoSys and Incyte.
  • Additional information related to 2023 Financial Guidance:
    Tremfya® royalties will continue to be recorded as revenue without any cost of sales in MorphoSys’ income statement.
  • MorphoSys Group Key Figures (IFRS, end of the second quarter: June 30, 2023)

EQS-News: MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Rituximab, Ruxolitinib, MorphoSys, European Hematology Association, Conference call, Hydroxycarbamide, JAK, ICML, American Society of Clinical Oncology, Lymphoma, Lenalidomide, Cancer, FSE, Incyte, ASCO, BET, Publication, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, EHA, Annual general meeting, Webcast, Society, Conference, Safety, Nursing, Pharmaceutical industry, Beauty salon, Tafasitamab

Minjuvi royalty revenue of € 2.2 million for sales outside of the U.S. in the second quarter 2023 and € 2.9 million for the first half of 2023.

Key Points: 
  • Minjuvi royalty revenue of € 2.2 million for sales outside of the U.S. in the second quarter 2023 and € 2.9 million for the first half of 2023.
  • The MorphoSys AG Annual General Meeting on May 17, 2023 re-elected Mr. George Golumbeski, Ph.D., and Mr. Michael Brosnan to the Company’s Supervisory Board.
  • Events After the End of the Second Quarter of 2023:
    On August 1, 2023, Incyte announced the full enrollment of the Phase 3 study inMIND.
  • Total revenues for the second quarter 2023 were € 53.2 million compared to € 59.4 million for the same period in 2022.

Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, August 8, 2023
Biometrics, Health, Pharmaceutical, Clinical Trials, Oncology, PDAC, APL, Completeness, Venetoclax, CDK7, Incyte, ID, RARA, ASCO, HR, AML, Azacitidine, Patient, Annual general meeting, CR, Webcast, Bone marrow, Research, Society, American Society of Clinical Oncology, Pfizer, Pharmaceutical industry, Medical imaging, Syros

Revenues were $2.8 million for the second quarter of 2023, consisting entirely of revenue recognized under Syros’ collaboration with Pfizer.

Key Points: 
  • Revenues were $2.8 million for the second quarter of 2023, consisting entirely of revenue recognized under Syros’ collaboration with Pfizer.
  • Research and development expenses were $29.6 million for the second quarter of 2023, as compared to $33.1 million for the second quarter of 2022.
  • General and administrative expenses were $7.2 million for the second quarter of 2023, as compared to $6.9 million for the second quarter of 2022.
  • ET to discuss these second quarter 2023 financial results and provide a corporate update.

Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update

Retrieved on: 
Monday, August 7, 2023
PDAC, Travel, CRPC, RECIST, Oncology, European Society for Medical Oncology, Patient, EGFR, National Medical Products Administration, Eli Lilly and Company, Prostate cancer, Disease, EAP, Afatinib, Mutation, ADT, Research, Lung cancer, Biologics license application, Drug design, CPS, MET, PD-1, FDA, PD-L1, Safety, Pancreatic cancer, Neoplasm, AACR, CD3, HER2, ESMO, Cancer, American Association for Cancer Research, BTD, NSCLC, IP, NRG1, Castration, Lilly, Depreciation, Pembrolizumab, ORR, Partnership, Betta, Clinical trial, OS, Cetuximab, FTD, Bank, Pharmaceutical industry, Medical imaging, Cryptocurrency, HNSCC, Incyte, Meru Wind Power Station

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter and provided a business update.

Key Points: 
  • In April, Merus provided an interim clinical update at the American Association for Cancer Research (AACR) Annual Meeting 2023.
  • Merus plans to provide initial clinical data on Zeno in CRPC in the second half of 2023.
  • The Company plans to provide an initial clinical data update from the expansion cohorts, and a further clinical development strategy update in the second half of 2023.
  • In July 2023, Merus achieved a milestone and expects a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.

Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer

Retrieved on: 
Thursday, August 3, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Pharmacy, University, GSK plc, Culture, Senior advisor, Cancer, Quality of life, Janssen, Pfizer, Incyte, Research, Dash, Chairperson, Acquisition, Patient, Janssen Pharmaceuticals, Drug discovery, University of Manchester Institute of Science and Technology, Northwestern University, Discovery science, Management, Pharmaceutical industry, Chemistry

Dashyant Dhanak, Ph.D., has been appointed Executive Vice President and Chief Scientific Officer effective September 5, 2023.

Key Points: 
  • Dashyant Dhanak, Ph.D., has been appointed Executive Vice President and Chief Scientific Officer effective September 5, 2023.
  • Dr. Dhanak brings over 30 years of experience in pharmaceutical research and development and joins Deciphera from Incyte Corporation where he was Executive Vice President and Chief Scientific Officer.
  • “We are excited to build on our track record of innovation in drug discovery with the announcement that Dash Dhanak is joining Deciphera as our new Chief Scientific Officer.
  • Jim’s deep industry expertise has been invaluable in guiding our research activities, scaling our organization, and transforming Deciphera into a leading commercial-stage oncology company.

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 3, 2023
Bevacizumab, Radiation, CRC, Skin, Roche, Clinical trial, Merkel-cell carcinoma, SCCHN, Data collection, Uveal melanoma, RP3, Incyte, SOC, Cisplatin, RP1, ASCO, ORR, CSCC, American Society of Clinical Oncology, Cytokine release syndrome, Patient, Standard of care, Melanoma, Carcinoma, CPS, Annual general meeting, Liver, Nivolumab, ATC, RP2, Kinetics, BLA, PD-L1, Society, Safety, Fatigue, Pharmaceutical industry, Vaccine, Medical imaging, Nursing

“It was a productive quarter with positive updates for RP1 in anti-PD1 failed melanoma and RP2 in uveal melanoma presented at ASCO.

Key Points: 
  • “It was a productive quarter with positive updates for RP1 in anti-PD1 failed melanoma and RP2 in uveal melanoma presented at ASCO.
  • S,G&A Expenses: Selling, general and administrative expenses were $15.2 million for the first quarter ended June 30, 2023, as compared to $11.4 million for the first quarter ended June 30, 2022.
  • Selling, general and administrative expenses included $5.5 million in stock-based compensation expenses for the first quarter ended June 30, 2023.
  • Net Loss: Net loss was $49.6 million for the first quarter ended June 30, 2023, as compared to a net loss of $42.3 million for the first quarter ended June 30, 2022.

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

Retrieved on: 
Monday, July 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Learning, Hematology, Clinical trial, Multimedia, RPX, RP1, Development, CSCC, Patient, Carcinoma, PD-L1, Safety, Pharmaceutical industry, Incyte

Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.

Key Points: 
  • Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.
  • This press release features multimedia.
  • Under the terms of the agreement, Incyte will initiate and sponsor the clinical trial of INCB99280 and RP1 in patients with high risk, resectable cutaneous squamous cell carcinoma (CSCC), with the clinical trial expected to initiate in early 2024.
  • Replimune will supply Incyte with RP1 for the study and share equally in the costs of the study.

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Retrieved on: 
Monday, July 24, 2023
SNDX, Biologics license application, GVHD, Macrophage, Event, Quality of life, Research, Inflammation, Today, Fibrosis, Vanderbilt-Ingram Cancer Center, Patient, Data, Lipase, Confidence interval, Kaplan–Meier estimator, FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, ORR, Food, Caregiver, Safety, Fatigue, Disease, Vaccine, Medical device, Pharmaceutical industry, Incyte

and WILMINGTON, Del., July 24, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy.

Key Points: 
  • and WILMINGTON, Del., July 24, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy.
  • Based on these results, and pending agreement from the U.S. Food and Drug Administration (FDA), Syndax and Incyte intend to submit a Biologics License Application (BLA) to the FDA by year-end 2023.
  • "Today marks an important day not only for Syndax and Incyte, but, more importantly, for patients suffering from chronic GVHD," said Michael A. Metzger, Chief Executive Officer of Syndax.
  • These results underscore our belief that axatilimab could provide a valuable and highly differentiated therapeutic option for this devastating disease.

bit.bio Strengthens Leadership Team With Appointment of Dr Michael Booth as Senior Vice President, External Affairs and Investor Relations

Retrieved on: 
Monday, June 12, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Corporate Affairs, Canaccord Genuity, University, Senior, Communication, Multimedia, Bachelor of Science, Regenerative medicine, Doctor of Philosophy, Division, Dynamics (music), Corporation, Drug discovery, CFO, Growth, Foreign policy, UBS, Bank, Synthetic biology, Management, Algeta, Psychology, Neuroscience, Incyte, Atlantic Ocean

bit.bio, the cell coding company, today announces the appointment of Dr Michael Booth as Senior Vice President, External Affairs and Investor Relations.

Key Points: 
  • bit.bio, the cell coding company, today announces the appointment of Dr Michael Booth as Senior Vice President, External Affairs and Investor Relations.
  • Dr Booth joins bit.bio from Crescendo Biologics where he was responsible for financial strategy and reporting as well as global investor relations and communications.
  • Dr Booth brings over 20 years’ experience in the capital markets, including leadership roles in investor relations and financial communications, making him a valuable addition to the bit.bio team.
  • Dr Michael Booth was most recently CFO at Crescendo Biologics where he was responsible for financial strategy and reporting as well as for global investor relations and communications.

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Docetaxel, Prostate-specific antigen, Therapy, Half-life, Conference call, Telephone, Food and Drug Administration, Merkel-cell carcinoma, Cancer, Macrogen, RPF, ID, Sale, Trial of the century, Acute myeloid leukemia, Lung, ASCO, B7, Endometrial cancer, Patient, DRI, Syndrome, CD123, MCC, Webcast, ADC, Johns Hopkins, Cytokine release syndrome, Enoblituzumab, PD-1, FDA, Research, Conference, PSA, Food, Prostate cancer, D, Pharmaceutical industry, Vaccine, Medical imaging, Internet service provider, Cryptocurrency, Nature Medicine, Incyte, Sanofi

ET

Key Points: 
  • ET
    ROCKVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2023.
  • MacroGenics initiated the Phase 2 portion of the TAMARACK study of vobra duo in patients with mCRPC in late 2022.
  • MacroGenics anticipates commencement of enrollment under the revised protocol beginning in the second quarter of 2023 and expects to provide a clinical update in 2024.
  • R&D Expenses: Research and development expenses were $45.9 million for the quarter ended March 31, 2023, compared to $61.4 million for the quarter ended March 31, 2022.